|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-26.75/-4.13
|
Enterprise Value
4.19M
|
Balance Sheet |
Book Value Per Share
0.41
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
--
|
Operating Revenue Per Share
0.25
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/05/16 07:26 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib. |